{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:42:53Z","timestamp":1784616173853,"version":"3.55.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jhepr.2019.05.005","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T07:57:09Z","timestamp":1565337429000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["New treatments\/targets for primary biliary cholangitis"],"prefix":"10.1016","volume":"1","author":[{"given":"Christophe","family":"Corpechot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chazouill\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2019.05.005_bb0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0015","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","article-title":"The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"67","author":"Hirschfield","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0025","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0035","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0040","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0045","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0050","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep.510250104","article-title":"Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis","volume":"25","author":"Medina","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0016-5085(99)70564-0","article-title":"Assessment of biliary bicarbonate secretion in humans by positron emission tomography","volume":"117","author":"Prieto","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0065","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0070","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.27715","article-title":"Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation","volume":"61","author":"Poupon","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0075","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jhep.2018.08.020","article-title":"Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?","volume":"69","author":"Rodrigues","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0080","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.29533","article-title":"MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation","volume":"67","author":"Erice","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clinre.2016.08.002","article-title":"Stress-induced cellular responses and cell death mechanisms during inflammatory cholangiopathies","volume":"41","author":"Sasaki","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0090","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/liv.12049","article-title":"Increased expression of mitochondrial proteins associated with autophagy in biliary epithelial lesions in primary biliary cirrhosis","volume":"33","author":"Sasaki","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0095","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000450983","article-title":"Bile Acid Uptake Transporters as Targets for Therapy","volume":"35","author":"Slijepcevic","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0105","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jhep.2009.11.027","article-title":"Primary biliary cirrhosis: a 2010 update","volume":"52","author":"Poupon","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2019.02.001","article-title":"Pathophysiology of Organ and Tissue Fibrosis","volume":"65","author":"Parola","year":"2019","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.05.016","article-title":"Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents","volume":"121","author":"Bottcher","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0120","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0125","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0130","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0135","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0140","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0145","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1046\/j.1365-2036.1998.00395.x","article-title":"A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg\/kg or 20 mg\/kg. Dutch Multicentre PBC Study Group","volume":"12","author":"Van Hoogstraten","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA- Cooperative Group from the Spanish Association for the Study of the Liver","volume":"32","author":"Pares","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0155","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","author":"Poupon","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0170","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0175","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0180","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1046\/j.1365-2036.2003.01792.x","article-title":"Systematic review: ursodeoxycholic acid--adverse effects and drug interactions","volume":"18","author":"Hempfling","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0185","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0190","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0195","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1021\/jm049904b","article-title":"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid","volume":"47","author":"Pellicciari","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0200","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0205","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0210","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0168-8278(18)30441-0","article-title":"Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis\/cirrhosis in patients with Primary Biliary Cholangitis (PBC)","volume":"68","author":"Bowlus","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0215","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0220","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0225","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/hq1101.098228","article-title":"Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression","volume":"21","author":"Post","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0230","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1042\/bj3140781","article-title":"Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse","volume":"314","author":"Chianale","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0235","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","article-title":"Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis","volume":"16","author":"Iwasaki","year":"1999","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0240","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","author":"Nakai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0245","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","author":"Ohira","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0250","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0255","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0260","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00535-014-0998-z","article-title":"Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA","volume":"50","author":"Tanaka","year":"2015","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0270","article-title":"Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis","author":"Kremer","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0275","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study","volume":"35","author":"Ting","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0280","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/apt.15049","article-title":"Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add-on in primary biliary cholangitis with incomplete UDCA response","volume":"49","author":"Corpechot","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0285","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0290","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0295","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0168-8278(18)30293-9","article-title":"Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid","volume":"68","author":"Hirschfield","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0300","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0305","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.gcb.2010.02.004","article-title":"Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone","volume":"34","author":"Rabahi","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0310","first-page":"1085A","article-title":"Alkaline phosphatase normalization is associated with a decreased risk for liver transplantation and death in patients with primary biliary cholangitis","volume":"68","author":"Murillo Perez","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0315","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0320","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0325","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/hep.30517","article-title":"Hepatology Elsewhere","volume":"69","author":"Pratt","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0330","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrgastro.2015.12","article-title":"Novel therapeutic targets in primary biliary cirrhosis","volume":"12","author":"Dyson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0335","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0340","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0345","article-title":"Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial","author":"Khanna","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0350","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0355","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0360","first-page":"1445A","article-title":"Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study","volume":"68","author":"Bowlus","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0365","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/S0618-8278(19)30226-9","article-title":"Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment","volume":"70","author":"Schattenberg","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0370","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0168-8278(18)30426-4","article-title":"Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study","volume":"68","author":"Schramm","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0375","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2017.01.013","article-title":"Steroidal or non-steroidal FXR agonists - Is that the question?","volume":"66","author":"Verbeke","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0380","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0385","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0390","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0395","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0400","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0405","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S0618-8278(19)30002-7","article-title":"Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial","volume":"70","author":"Dalekos","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2019.05.005_bb0410","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555919300539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555919300539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:23:58Z","timestamp":1762899838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555919300539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2589555919300539"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2019.05.005","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatments\/targets for primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2019.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}]}}